Influence of Cyclooxygenase-2 (COX-2) Gene Promoter Polymorphism at Position −765 on Skin Cancer after Renal Transplantation  by Aubin, François et al.
Influence of Cyclooxygenase-2 (COX-2) Gene Promoter
Polymorphism at Position 765 on Skin Cancer after
Renal Transplantation
Journal of Investigative Dermatology (2010) 130, 2134–2136; doi:10.1038/jid.2010.116; published online 6 May 2010
TO THE EDITOR
Skin cancer is the most prevalent
cancer in humans, and its incidence
is 4–20 times higher in renal transplant
recipients (RTRs; Grulich et al., 2007)
than in immunocompetent subjects,
reaching an estimated incidence of
40–75% 20 years after transplantation
(Moloney et al., 2006). Hyperexpres-
sion of cyclooxygenase 2 (COX-2)
catalyzes the first step in the synthesis
of prostaglandins, which may then
function as tumor promoters or en-
hance initiation as oxidants (Rundhaug
and Fischer, 2008). Furthermore,
prostaglandin E2 (PGE2) induces
FOXP3 gene expression and T regula-
tory cell function in human CD4þ T
cells (Baratelli et al., 2005), which may
contribute to the immune escape of
UV-mutated clones and ultimately lead
to skin cancer (Beissert and Schwarz,
2009). A frequently occurring func-
tional G-C polymorphism has been
identified in the human COX-2 gene
promoter at position 765, with the C
allele leading to a decreased promoter
activity with low PGE2 production
(Papafili et al., 2002; Mu¨ller-Decker
and Fu¨rstenberger, 2007).
We conducted a study to investigate
the association of the COX-2 gene
promoter polymorphism at position
765 with skin cancers in RTRs. Our
working hypothesis was that RTRs carry-
ing the C allele and consequently ex-
hibiting reduced PGE2 production could
experience less skin cancer due to the
loss of the PGE2-promoting activity.
STUDY DESIGN AND POPULATION
Two cohorts of RTRs were investigated,
including 365 patients from Besanc¸on
and 238 patients from Paris. The study
design was approved by the research
ethics committee of Besanc¸on Univer-
sity Hospital, and all patients provided
written informed consent before enroll-
ment. The study adhered to the Decla-
ration of Helsinki protocols. Skin can-
cer history was analyzed as a covariate.
DNA EXTRACTION AND ANALYSIS
OF COX-2 GENE PROMOTER
POLYMORPHISM AT POSITION
765 (G-C)
Genomic DNA (gDNA) was obtained
from peripheral blood leukocytes.
Analysis of the COX-2 gene promoter
loci was done using a PCR-based
genotyping assay (Papafili et al., 2002;
Courivaud et al., 2009). Primer se-
quences used were 50-CCGCTTCCTTT
GTCCATCAG-30 and 50-GGCTGTATAT
CTGCTCTATATGC-30. After PCR am-
plification of the polymorphism regions
of interest (306 bp in length), the
products were digested overnight with
AciI restriction endonuclease (New
England Biolabs, Beverly, CA). After
separation by a 2% standard agarose
gel electrophoresis, the digested PCR
products of homozygous wild-type
DNA were 188 and 118bp in length
(GG). Bands of three sizes (digested and
undigested) were present in heterozy-
gous DNA (GC). One band size (un-
digested) was present in muted
homozygous DNA (CC). For each
PCR, a negative control (PCR amplifi-
cation without gDNA) was included.
The functional characterization of this
COX-2 gene promoter polymorphism
was validated in 62 RTRs in a previous
study (Courivaud et al., 2009) by
measuring circulating PGE2 levels
using a highly sensitive ELISA kit
(R&D Systems, Lille, France).
STATISTICAL ANALYSIS
For normally distributed variables, C
carriers and GG carriers were com-
pared using the w2 test for dichotomic
variables and Student’s t test for
continuous variables. Hardy–Weinberg
equilibrium was assessed for the geno-
type distribution.
STUDY POPULATION
Three hundred and sixty-five patients
from Besanc¸on (cohort 1) were fol-
lowed up for a mean duration of
9.5±10 years after transplantation.
The mean age at transplantation was
47±13.5 years, and 228 RTRs (62.5%)
were men. Skin cancers occurred in 28
patients (7.7%), which included 11
cases of squamous cell carcinoma
(SCC), 13 cases of basal cell carcinoma
(BCC), 3 cases of both SCC and BCC,
and 1 case of melanoma. Two hundred
and thirty-eight patients from Paris
(cohort 2) were followed up for a mean
duration of 8.5±3.7 years after trans-
plantation. The mean age at transplan-
tation was 45±12.5 years, and 134
(56.3%) were men. Skin cancer oc-
curred in 16 patients (6.7%), which
included 5 cases of SCC, 7 cases of
BCC, 3 cases of both SCC and BCC, and
1 case of melanoma.
RELATION BETWEEN THE COX-2
GENE PROMOTER POLYMORPHISM
AND SKIN CANCER
Briefly, there was no difference in the
distribution of the three genotypes in
the two cohorts (Table 1). The observed
allele frequencies were in Hardy–Wein-
berg equilibrium. In cohort 1, among
the RTRs with skin cancer, 12 patients
(9.6%) were C carriers and 16/240
(6.7%) were GG patients. In cohort 2,
Abbreviations: BCC, basal cell carcinoma; CI, confidence interval; COX-2, cyclooxygenase 2; gDNA,
genomic DNA; HR, hazard ratio; PGE2, prostaglandin E2; RTR, renal transplant recipient; SCC,
squamous cell carcinoma
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among the RTRs with skin cancer, 5
patients (6.7%) were C carriers and 11
(6.7%) were GG patients. Statistical
analysis showed no difference between
the genotypic distribution of RTRs pre-
senting with skin cancer and the geno-
typic distribution of those without a
history of skin cancer. In univariate
analysis, only age at transplantation
(P¼0.008 and P¼0.021, respectively)
was associated with skin cancer. Cox
regression analysis revealed that age at
transplantation (hazard ratio (HR) 1.51;
95% confidence interval (CI) 1.33–2.45
and HR 1.39; 95% CI 1.12–1.85) was
the only independent risk factor for skin
cancer (P¼ 0.011 and P¼0.034,
respectively).
CONCLUSION
We did not observe any significant
difference in the genotype distribution
of COX-2 gene promoter polymorphism
in RTRs between those with and those
without skin cancer. Both C and GG
carriers were predominant in RTRs
without a history of skin cancer and,
conversely, less common among RTRs
with skin cancer. We previously de-
monstrated that C carriers have lower
serum PGE2 levels in a transplantation
setting (Courivaud et al., 2009).
Our study does not confirm previous
results, suggesting the protective effect
of the COX-2 gene promoter poly-
morphism at position 765 for BCC in
RTRs (Lira et al., 2007). However, this
protective effect showed significance
only in a subgroup of individuals (BCC
patients who underwent transplantation
before 50 years of age).
The discrepancy with our data might
be explained by several hypotheses.
First, we cannot exclude a limited
statistical power due to the small
number of BCC cases in our study
(5 BCC cases among 26 patients o50
years of age). This is a significant
concern because our statistical power
calculation indicated that we would
require at least 5 times this number of
cases to detect a true effect size of
p2.0. For the difference observed in
our study (GG versus CC and CG), this
demonstration would require two co-
horts comprising 6,322 RTRs—i.e.,
12,644 RTRs—to demonstrate a risk
below 2. Second, the effects of poly-
morphisms can vary from tissue to
tissue, especially for inducible genes
such as COX-2 (Szczeklik et al., 2004),
through the loss of an Sp1 transcription
binding site induced by the 765C
variant along with the creation of a
binding site for E2F, which is a cyclin-
dependent regulator of expression of
several genes (Papafili et al., 2002).
Third, the potentially protective effect
of the 765C allele may be abolished
by the additive effects of other risk
factors, such as human papillomavirus
infection and UV exposure. Indeed,
COX-2 765C gene promoter poly-
morphism was associated with an
increased risk of colorectal cancer
(Xing et al., 2008) or peptic ulcer
disease (Saxena et al., 2008) only in
the presence of smoking and a high
body mass index or Helicobacter pylori
infection, respectively.
In conclusion, despite the weak
statistical power, our data suggest that
the COX-2 genotype does not represent
a major risk factor for skin cancer in
RTRs. However, given our small case
numbers, we cannot exclude the possi-
bility that this genotype may have a
minor role in a subgroup of patients.
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TO THE EDITOR
Behc¸et’s disease (BD) is a chronic,
relapsing, systemic vasculitis of un-
known etiology. Patients with BD ex-
hibit elevated levels of proinflammatory
cytokines and the affected organs show
a significant neutrophile and lympho-
cyte infiltration. Current evidence sug-
gest that the activated lymphocytes
contribute to neutrophile and endothe-
lial cell activation in these patients
(Akman et al., 2007; Alpsoy et al.,
2007). Recently, a new subset of Th
cells, Th17 cells, in part characterized
by their production of IL-17 has been
identified and their roles in inflamma-
tion or immune regulation are under
intensive investigation. IL-17 promotes
inflammation by inducing various
proinflammatory cytokines and chemo-
kines; it modulates the secretion of IL-1,
tumor necrosis factor-a, IL-6, IL-8, and
prostaglandin E2. IL-17 also increases
CXC chemokine secretion. Therefore,
IL-17 causes neutrophil influx and
regulates neutrophil-mediated inflam-
matory responses. Th17 cells have the
most remarkable effects on neutrophil
activity within T-cell sub-populations
(Furuzawa-Carballeda et al., 2007). It is
well known that neutrophil activity is
increased in BD. Again, IL-6, IL-1, and
tumor necrosis factor-a, which have a
role in the differentiation of naive T
cells to Th17 cells, are found
to be elevated in patients with BD
(Fossiez et al., 1996; Akman et al.,
2006). Serum G-CSF level was also
reported significantly higher in active
patients than in those inactive patients
with BD (Kawakami et al., 2004).
In a recent study, Chi et al. (2008)
have shown elevated production of
IL-17, IL-23, and IFN-g by peripheral
blood mononuclear cells (PBMC) be-
sides increased frequencies of IL-17 and
IFN-g-producing T cells in BD patients
with active uveitis. In this study, we
particularly aimed at investigating
the role of IL-17A in the activity and
different organ involvements of the
disease.
Forty-five patients (24 women,
21 men; mean age, 40 years) with BD,
diagnosed according to the criteria of
the International Study Group for BD
(1990), and 33 age- and sex-matched
healthy volunteers (17 women, 16 men;
mean age, 36 years) were enrolled in
the study. The study was approved
by the Ethics Committee of Akdeniz
University (Institutional approval num-
ber: 2007.02.0122007). Informed con-
sent was obtained from all participants,
and study was conducted according to
the Declaration of Helsinki Principles.
Control group had neither family
history nor symptoms related to BD.
Twenty-two patients (10 women,
12 men, mean age 41) with BD were
at inactive stage, whereas 23 of them
(14 women, 9 men, mean age 39 years)
were at active stage. Any patient having
any active sign of the disease at the time
of blood drawn was accepted at active
stage. All patients had oral ulcers, and
in 16 of them this finding was at active
stage. The same figure was 16 and 2
for genital ulcers, 13 and 1 for erythema
nodosum, 23 and 6 for articular
involvement, 18 and 8 for ocular
symptoms. In addition, six patients
had vascular, and two gastrointestinal
involvement.
We examined serum levels of IL-17A
by ELISA. In vitro IL-17A response of
PBMC of patients with BD and controls
after stimulation with Streptococcus
sanguis (S. sanguis), Escherichia coli
(E. coli), and phytohemaglutinin
were evaulated by enzyme-linked
immunosorbent spot method. The
proportion of IL-17A-secreting cells
(Th17 cells) in nine patients with active
organ involvement and nine healthyAbbreviations: BD, Behc¸et’s disease; PBMC, peripheral blood mononuclear cells
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